



October 19, 2023

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001	National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai 400 051
BSE Scrip Code: 500247, 715026, 958687, 974396, 974682, 974924	NSE Symbol: KOTAKBANK, KMBL, KMB26, KMB29, KMB30

Dear Sirs,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In accordance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform you that Kotak Alternate Asset Managers Limited (earlier known as Kotak Investment Advisors Limited), a wholly-owned subsidiary of the Bank has acquired 1,29,870 nos. of Compulsorily Convertible Preference Shares (“CCPS”) of NKURE THERAPEUTICS PRIVATE LIMITED (“NKURE”) on October 18, 2023, upon conversion of 10,00,000 nos. of Compulsorily Convertible Debentures (“CCDs”) at a price of Rs. 77 per CCPS, constituting acquisition of 6.12% of the paid-up share capital of NKURE.

The details of the above acquisition, as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III and the SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, are enclosed as Annexure A.

We request you to take the above on record and disseminate the same on your website.

Thanking you,

Yours faithfully,

For Kotak Mahindra Bank Limited

Avan Doomasia
Company Secretary

Encl.: as above

Annexure A

a.	Name of the target entity, details in brief such as size, turnover etc.	NKURE THERAPEUTICS PRIVATE LIMITED (“NKURE”) is a private limited company, incorporated in India on February 11, 2022 under the provisions of the Companies Act, 2013. NKURE did not have any revenue in FY23 and has not started commercial activities.
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	The acquisition does not fall within related party transaction. The promoter/ promoter group/ group companies of Kotak Mahindra Bank Limited (“Bank”) have no interest in NKURE.
c.	Industry to which the entity being acquired belongs	NKURE is principally engaged to undertake research in using cells and their derivatives to generate therapeutic products to treat cancer and cancer related pathology. The investment would facilitate development by NKURE of novel therapeutic products for cancer.
d.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	
e.	Brief details of any governmental or regulatory approvals required for the acquisition	None
f.	Indicative time period for completion of the acquisition	The transaction was completed on October 18, 2023.
g.	Consideration - whether cash consideration or share swap and details of the same	Conversion of 10,00,000 nos. of CCDs into 1,29,870 nos. of CCPS
h.	Cost of acquisition and/or the price at which the shares are acquired	Rs. 77 per CCPS (for conversion of 10,00,000 nos. of CCDs into 1,29,870 nos. of CCPS)
i.	Percentage of shareholding / control acquired and / or number of shares acquired	Acquired 1,29,870 nos. of CCPS, constituting 6.12% of the paid-up share capital of NKURE on fully diluted basis
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	NKURE is a private limited company, incorporated in India on February 11, 2022 under the provisions of the Companies Act, 2013. NKURE is principally engaged to undertake research in using cells and their derivatives to generate therapeutic products to treat cancer and cancer related pathology. NKURE has not started commercial activities.